9578 completed, 3164 terminated, 2822 recruiting, 1896 unknown. 20626 Phase 1, 7295 Phase 2.
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | German Cancer Research Center | 12 | 2028-01-01 | 2025-03-14 |
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin) - Neuroblastoma (NBL), Ewing Sarcoma | Phase 1 | Not yet recruiting | Universität Münster | 30 | 2027-10-01 | 2026-11-03 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Combination Immunotherapy Targeting Sarcomas Multiple sarcoma-specific CAR-T cells and sarcoma vaccines - Sarcoma, Osteoid Sarcoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-07-01 | 2026-11-02 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Universal CAR-T Cells Targeting AML CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-30 | 2026-11-02 |
| REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) - Metastatic Castration-Resistant Prostate Cancer, mCRPC | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 192 | 2027-06-28 | 2026-09-30 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-11-06 |
| The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck Nutrition counseling, Fresubin Supportan - Head &Amp;Amp; Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Anna Arthur, PhD | 15 | 2027-06-01 | 2026-08-07 |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-09-15 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 |
Showing 20 of 20626. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (1977) · Breast Neoplasms (1877) · Leukemia, Myeloid, Acute (1478) · Neoplasm Metastasis (1298) · Colorectal Neoplasms (1248) · Melanoma (1215) · Multiple Myeloma (1192) · Lymphoma (1069) · Prostatic Neoplasms (1065) · Pancreatic Neoplasms (1055) · Ovarian Neoplasms (1024) · Recurrence (965) · Lymphoma, Non-Hodgkin (963) · Lung Neoplasms (867)
Neoplasms by Site (11970) · Neoplasms by Histologic Type (11587) · Hemic and Lymphatic Diseases (6121) · Immune System Diseases (4621) · Immunoproliferative Disorders (4504) · Neoplasms, Glandular and Epithelial (4478) · Lymphoproliferative Disorders (4475) · Hematologic Diseases (4290) · Digestive System Diseases (3775) · Pathological Conditions, Signs and Symptoms (3688) · Digestive System Neoplasms (3664) · Lymphatic Diseases (3615) · Pathologic Processes (3503) · Urogenital Diseases (3415)
Cyclophosphamide (966) · pembrolizumab (798) · Gemcitabine (627) · Carboplatin (623) · Paclitaxel (580) · Cisplatin (575) · Radiotherapy (569) · Nivolumab (539) · fludarabine (537) · Dexamethasone (432) · Bevacizumab (412) · Rituximab (383) · Docetaxel (366) · Cytarabine (336) · Lenalidomide (324)
National Cancer Institute (NCI) (1066) · M.D. Anderson Cancer Center (649) · Memorial Sloan Kettering Cancer Center (371) · Novartis Pharmaceuticals (281) · AstraZeneca (215) · City of Hope Medical Center (202) · Pfizer (193) · Washington University School of Medicine (179) · GlaxoSmithKline (178) · Hoffmann-La Roche (175) · Merck Sharp & Dohme LLC (173) · Eli Lilly and Company (169) · Dana-Farber Cancer Institute (167) · Bristol-Myers Squibb (164) · Mayo Clinic (154)
United States (13000) · China (2829) · Spain (1454) · France (1383) · Canada (1248) · United Kingdom (1184) · Australia (1098) · Germany (956) · South Korea (872) · Italy (842) · Japan (794) · Netherlands (699) · Belgium (600) · Taiwan (455) · Israel (330)
PMID 34515338, PMID 31401903, PMID 41671463, PMID 39863139, PMID 19238148, PMID 34398557, PMID 28054442, PMID 36897458, PMID 22473314, PMID 38172595, PMID 39462179, PMID 32379297, PMID 32499241, PMID 32827353, PMID 33465252, PMID 33883258, PMID 35622074, PMID 37093350, PMID 40443562, PMID 41429239, PMID 42013378, PMID 23400739, PMID 24919854, PMID 30120268, PMID 31355467, PMID 32770353, PMID 34780125, PMID 35468680, PMID 36100310, PMID 36383907, PMID 36648215, PMID 37022569, PMID 37598000, PMID 38753757, PMID 39319495, PMID 39813680, PMID 40056080, PMID 42820295, PMID 16394300, PMID 19192962, PMID 22658127, PMID 22658128, PMID 24577748, PMID 24615776, PMID 24615777, PMID 24668327, PMID 25475068, PMID 26943915, PMID 27240885, PMID 28803351
2023 (275), 2015 (145), 2016 (140), 2017 (138), 2019 (130), P30CA033572 (126), 2018 (125), 2025 (125), 2014 (104), P30CA016672 (80), 2009 (77), P30CA015704 (69), P30CA015083 (60), 2008 (49), U01CA076576 (45)